Amyotrophic Lateral Sclerosis (ALS) without Frontotemporal Dementia (FTD) is a distinct form of the neurodegenerative disease where motor neurons are progressively damaged, leading to muscle weakness, but without the cognitive and behavioral changes characteristic of FTD. This condition is also known as ALS-FTD spectrum disorder, emphasizing its nature as a spectrum where some individuals may develop FTD symptoms later. While the underlying causes are still being researched, the presence of certain genetic factors can increase the risk for both ALS and FTD.
Amyotrophic lateral sclerosis (ALS) is a progressive nerve disease that damages the motor neurons—the “wires” that carry movement signals from the brain and spinal cord to the muscles. Over time, these motor neurons die. When the signal is lost, the muscle becomes weak, tight or stiff, twitches, and wastes away. ALS does not usually affect the senses (vision, hearing, touch, smell, taste), the bladder and bowel early on, or the ability to think clearly.
This guide focuses on ALS without frontotemporal dementia (FTD). That means the person has ALS, but their memory, personality, and decision-making are mostly preserved. They may still feel low mood, anxiety, or emotional lability (sudden laughing or crying), but they do not have the severe behavior and language problems seen in ALS with FTD.
Amyotrophic lateral sclerosis (ALS) is a serious disease that slowly damages the nerve cells that control muscles. These nerve cells are called motor neurons. They live in the brain and spinal cord. In ALS they become weak, stop working, and die. When motor neurons die, muscles cannot get signals. Muscles then become weak, thin, and stiff. Over time, people have trouble walking, using their hands, speaking, swallowing, and breathing. In this article we talk about ALS without frontotemporal dementia (FTD). That means thinking, behavior, and personality are mostly normal or only mildly affected. Many people with ALS keep a clear mind. ALS usually does not cause pain directly, but cramps, stiffness, and immobility can hurt. There is no known cure yet, but medicines, therapies, and supportive care can slow decline, reduce symptoms, prevent complications, and improve quality of life. A strong, coordinated care plan makes a big difference.
ALS can start in the arms or legs (limb-onset) or in the speech and swallowing muscles (bulbar-onset). It tends to spread to other body parts over months to years. Breathing muscles are usually affected later in the illness.
Other names
Motor neuron disease (MND) — umbrella term used in many countries
Lou Gehrig’s disease — common name in North America
Charcot’s disease — historical term
Sporadic ALS — ALS with no clear family history
Familial ALS — ALS due to inherited gene changes (but still without FTD in this guide)
Note: Primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA) are closely related motor neuron disorders. Some people first look like these patterns and later meet criteria for ALS. They are often discussed alongside ALS but are not the same diagnosis.
Types and clinical patterns
Limb-onset ALS: Starts with hand clumsiness, foot drop, finger weakness, shoulder weakness, or leg stiffness. This is the most common pattern.
Bulbar-onset ALS: Starts with slurred or nasal speech, hoarse voice, drooling, or choking on liquids/foods.
Respiratory-onset ALS (less common): Early breathlessness, morning headaches, or disturbed sleep from weak breathing muscles before obvious limb weakness.
Upper-motor-neuron-predominant ALS: Stiffness, slowed movements, and brisk reflexes dominate early.
Lower-motor-neuron-predominant ALS: Muscle wasting, weakness, cramps, and visible twitches dominate early.
Regional phenotypes: “Flail arm” (mainly shoulder/arm weakness) or “flail leg” (mainly leg weakness) patterns can persist for a while before spreading.
Sporadic vs familial: Most cases are sporadic (no family history). About 5–10% are familial (inherited gene changes).
Causes
ALS cause is multifactorial. In most people, there is no single trigger you can point to. Scientists see a mix of genes, cell stress, and environmental factors. Below are 20 contributors and risk factors that research has linked to ALS. Some are causal in familial ALS (gene mutations). Others are associations or mechanisms that likely play a role.
C9orf72 gene expansion (familial): An abnormal repeat of DNA letters can damage motor neurons through toxic RNA and proteins. People can have ALS without FTD even with this gene.
SOD1 mutations (familial): Faulty antioxidant enzyme leads to toxic protein build-up and oxidative stress in motor neurons.
TARDBP (TDP-43) mutations (familial): TDP-43 protein misfolds and clumps, disrupting RNA handling inside neurons.
FUS mutations (familial): Changes in the FUS protein harm how cells process RNA and respond to stress.
Other rare genes (familial): OPTN, VCP, UBQLN2, TBK1, ANG, SQSTM1 and others each disturb waste-clearing, stress response, or energy systems in neurons.
Protein misfolding and aggregation: Misfolded proteins (often TDP-43) collect in motor neurons and interfere with cell function.
Glutamate excitotoxicity: Too much glutamate (a brain messenger) overstimulates neurons, letting in excess calcium that injures and kills cells.
Oxidative stress: Harmful oxygen molecules (free radicals) damage cell parts when the body’s defenses are overwhelmed.
Mitochondrial dysfunction: The cell’s “power stations” do not make energy well, leading to energy failure and cell death.
Impaired autophagy/proteasome (waste removal): The cell’s garbage disposal and recycling systems slow down, so toxic proteins accumulate.
Axonal transport failure: Cellular “railways” that move nutrients and signals along the nerve fiber break down.
Neuroinflammation: Support cells (microglia, astrocytes) release inflammatory signals that can worsen neuron injury.
RNA processing errors: Faulty splicing and handling of RNA disrupt many cellular jobs at once.
Environmental toxins (association): Long-term exposure to certain pesticides, solvents, or heavy metals has been linked to higher ALS risk in some studies.
Cyanobacteria/β-MAA exposure (hypothesized): Toxins from blue-green algae have been discussed as possible risk factors in specific settings.
Smoking (risk factor): Smoking is associated with higher risk of ALS, possibly via oxidative stress and inflammation.
Head/neck trauma (association): Repeated head impacts may increase risk in some populations, though research findings vary.
Intense physical exertion (association): Some studies suggest higher risk with very high-level or prolonged intense activity; results are mixed.
Immune dysregulation: Abnormal immune signaling may add to damage or fail to protect stressed neurons.
Aging: Age is the strongest risk factor. Aging lowers repair capacity and increases the chance of protein and DNA damage.
Important note: For most individuals with ALS, no single exposure explains the disease. Even when a gene mutation is present, the pace and pattern of ALS likely depend on many other factors.
Symptoms
Muscle weakness: The most common first sign. A hand cannot grip as before, or a foot drags (foot drop). Tasks feel harder.
Muscle wasting (atrophy): The weak muscle slowly shrinks because it is no longer getting strong nerve signals.
Muscle twitches (fasciculations): Small, ripple-like movements under the skin due to irritated or dying motor units.
Muscle cramps and tightness: Painful squeezing or ongoing stiffness in calves, hands, or thighs; often worse at night.
Spasticity (stiffness): Muscles resist movement; joints feel tight; gait looks stiff. This comes from upper motor neuron injury.
Slowed or clumsy movement: Buttons, keys, steps, or fine tasks become slow and awkward.
Brisk reflexes and Babinski sign: Tapping the tendon gives an exaggerated kick; the big toe may go up. These are upper motor neuron signs.
Speech changes (dysarthria): Slurred, nasal, or hoarse speech; words run together; voice tires easily.
Swallowing trouble (dysphagia): Coughing or choking with water; prolonged meals; weight loss because eating is hard.
Breathlessness (dyspnea), especially when lying down: Weak breathing muscles cause shortness of breath, morning headaches, and poor sleep.
Excess saliva (sialorrhea): Saliva builds up due to swallowing weakness; drooling can occur.
Pseudobulbar affect: Sudden laughing or crying that is hard to control; emotions feel “too strong” for the situation.
Fatigue and weight loss: Effortful movement and swallowing burn energy; muscles also use more energy as they weaken.
Neck or head drop: Neck extensor weakness leads to difficulty holding the head up.
Falls: Legs can buckle or misstep due to a mix of weakness, stiffness, and poor balance.
Sensation (touch, pain, temperature) and eye movement are usually normal in ALS. Bladder and bowel often remain okay until late disease.
Diagnostic tests
A) Physical examination
Comprehensive neurological exam: The clinician checks strength, muscle bulk, tone, reflexes, coordination, and sensation. In ALS, there is a mix of upper motor neuron signs (brisk reflexes, spasticity) and lower motor neuron signs (wasting, twitches, weakness) in several body regions. Sensation is mostly normal, which helps separate ALS from many neuropathies.
Cranial nerve and bulbar exam: The doctor listens to speech, watches tongue movement, checks palate lift, and tests swallowing and gag. Slurred or nasal speech, tongue atrophy and fasciculations, and weak palate suggest bulbar involvement.
Gait and posture assessment: Observing walking, turning, heel/toe walking, and posture helps reveal foot drop, stiff gait, poor arm swing, or head drop.
Respiratory assessment at bedside: The clinician checks breathing rate, use of accessory muscles, ability to count on one breath, and cough strength to screen for respiratory muscle weakness.
B) Manual and functional tests
Manual Muscle Testing (MMT) with the MRC scale: The examiner grades strength from 0 to 5 using hands to resist movement. It maps which muscle groups are weak and tracks change over time.
Grip dynamometry: A handheld device measures grip force precisely. It is simple, repeatable, and sensitive to small changes in hand strength.
Nine-Hole Peg Test (dexterity): Timed test of finger speed and coordination; useful when hand clumsiness is an early complaint.
Timed Up and Go (TUG) or 10-Meter Walk Test: Short walking tests that capture mobility, balance, and fall risk. Worsening times reflect progression.
C) Laboratory and pathological tests
Serum creatine kinase (CK): CK may be mildly raised from ongoing muscle damage but is usually lower than in primary muscle diseases. Helps with differential diagnosis.
Rule-out blood tests: Vitamin B12, thyroid profile, autoimmune markers, HIV, HTLV-1, Lyme (where relevant), and others help exclude treatable mimics of ALS.
Genetic testing (when indicated): Panels that include C9orf72, SOD1, TARDBP, FUS and others can confirm familial ALS or inform clinical trials, even when no dementia is present.
Muscle or nerve biopsy (selected cases): Rarely needed; used when the picture is unclear, to rule out inflammatory neuropathies or primary muscle disease. In classic ALS, biopsy typically isn’t required.
D) Electrodiagnostic tests
Electromyography (EMG): Thin needle electrodes record electrical activity inside muscles. In ALS, EMG shows signs of active denervation (fibrillations, positive sharp waves) and chronic reinnervation (large motor units), across multiple regions. This is a key test.
Nerve conduction studies (NCS): Measure how fast and how strong signals travel along nerves. In ALS, sensory studies are usually normal, which helps separate ALS from sensory neuropathies; motor studies may show reduced amplitudes.
Transcranial magnetic stimulation (TMS) for central motor conduction: Assesses how quickly the brain’s motor signal reaches the muscle. Delays suggest upper motor neuron pathway involvement.
Repetitive nerve stimulation (to exclude myasthenia gravis): If speech, swallow, or eyelid fatigue suggests a junction disorder, this test helps rule it out.
E) Imaging tests
MRI brain: Not to “see ALS,” but to exclude stroke, tumor, or other structural problems that can mimic upper motor neuron signs. Sometimes subtle corticospinal tract changes appear, but MRI mainly rules out other causes.
MRI cervical and thoracic spine: Looks for cord compression, myelopathy, or root disease that could explain limb weakness or reflex changes.
Diaphragm ultrasound (or fluoroscopy sniff test): Noninvasive way to see diaphragm movement. Reduced or paradoxical motion indicates respiratory muscle weakness.
Muscle ultrasound: Can show fasciculations and muscle thinning at the bedside, supporting lower motor neuron involvement and helping follow progression.
Together, the history, exam, EMG/NCS, and imaging to exclude mimics allow clinicians to apply accepted diagnostic criteria (for example, El Escorial or Gold Coast criteria) to make the diagnosis of ALS.
Non-pharmacological treatments (therapies and others)
(Each item includes description, purpose, and mechanism explained in plain English.)
Multidisciplinary clinic care
Description: Regular visits with a team—neurologist, nurse, respiratory therapist, physical therapist, occupational therapist, speech-language pathologist, dietitian, social worker, and palliative care.
Purpose: Coordinate decisions, plan ahead, and treat problems early.
Mechanism: Team care reduces gaps in treatment, improves nutrition and breathing planning, and speeds equipment access.Respiratory therapy and non-invasive ventilation (NIV)
Description: Breathing support using a mask (for example, BiPAP) at night and later daytime.
Purpose: Ease shortness of breath, improve sleep, reduce headaches, and extend life.
Mechanism: A small machine pushes air in and out, lowering the work of breathing and helping tired breathing muscles.Airway clearance training
Description: Techniques such as breath-stacking, manually assisted cough, mechanical insufflation–exsufflation (“cough assist”), and suction.
Purpose: Clear mucus, prevent chest infections, and reduce hospital visits.
Mechanism: Increases airflow and pressure to move secretions from the lungs to the mouth where they can be cleared.Speech-language therapy (SLT)
Description: Exercises, pacing, voice banking, speech devices, and strategies to keep communication clear.
Purpose: Maintain safe swallowing and effective speaking for as long as possible.
Mechanism: Trains safer swallow patterns and introduces augmentative and alternative communication (AAC) tools.Augmentative & alternative communication (AAC)
Description: From simple letter boards to tablets, eye-gaze systems, and text-to-speech.
Purpose: Keep independence in communication as speech weakens.
Mechanism: Bypasses weak speech muscles by using hands, eyes, or head movements to produce text or voice.Swallow therapy & diet texture modification
Description: Thickened liquids, softer foods, chin-tuck and head-turn maneuvers, smaller bites, and upright posture.
Purpose: Reduce choking and aspiration; maintain hydration and weight.
Mechanism: Changes food flow and body position so weak muscles can move food more safely.Nutrition therapy & high-calorie planning
Description: Personalized meal plans with extra calories and protein; timing snacks when energy is better.
Purpose: Prevent weight loss and malnutrition, which are linked to faster decline.
Mechanism: High-energy foods compensate for muscle wasting and the extra effort of breathing.Early gastrostomy planning (PEG or RIG)
Description: Placing a feeding tube before breathing is too weak, while it is still safe to do.
Purpose: Ensure reliable nutrition and oral medication delivery when eating becomes hard.
Mechanism: Provides direct access to the stomach, preventing aspiration and weight loss.Physical therapy (PT) for movement and posture
Description: Gentle range-of-motion, stretching, balance work, and transfer training—never to exhaustion.
Purpose: Reduce stiffness, cramps, and contractures; maintain safe mobility.
Mechanism: Keeps joints flexible and retrains safer movement patterns around weak muscles.Occupational therapy (OT) & adaptive equipment
Description: Training with braces, splints, wheelchair seating, powered mobility, transfer boards, and bathroom aids.
Purpose: Make daily tasks safer and easier.
Mechanism: External supports replace lost muscle function and save energy.Energy conservation & fatigue management
Description: Pacing, scheduled rests, breaking tasks into steps, and using devices instead of muscle power.
Purpose: Preserve energy for the most important activities.
Mechanism: Reduces total metabolic demand and prevents “overwork weakness.”Spasticity & contracture prevention program
Description: Daily stretches, proper seating, night splints, and heat packs as tolerated.
Purpose: Ease stiffness and prevent fixed joint bending.
Mechanism: Regular lengthening of muscles and tendons lowers reflex over-activity.Cramp and pain self-management
Description: Gentle stretching before bed, massage, warm baths, and consistent hydration.
Purpose: Decrease night cramps and aching.
Mechanism: Warmth and stretching reduce muscle excitability and improve blood flow.Falls prevention & home safety
Description: Clear pathways, non-slip shoes, grab bars, stair rails, and transfer training for caregivers.
Purpose: Avoid fractures, head injury, and fear of moving.
Mechanism: Environmental changes and safer techniques reduce risk.Pressure injury prevention
Description: Repositioning schedules, pressure-relieving cushions or mattresses, and skin checks.
Purpose: Prevent bedsores and infections.
Mechanism: Reduces prolonged pressure and improves skin blood flow.Psychological support & counseling
Description: Supportive psychotherapy, coping skills, and caregiver counseling.
Purpose: Manage sadness, anxiety, grief, and stress; protect relationships.
Mechanism: Evidence-based approaches (CBT elements, problem-solving) improve resilience.Peer support & patient advocacy groups
Description: Support groups (in-person or online), connecting with others living with ALS.
Purpose: Reduce isolation; share practical tips and resources.
Mechanism: Social connection and knowledge exchange improve mental well-being and self-efficacy.Advance care planning
Description: Discuss wishes about feeding tubes, ventilation, hospital care, and palliative options early.
Purpose: Ensure care matches personal values.
Mechanism: Written plans guide clinicians and family when decisions are urgent.Vaccinations and infection-prevention habits
Description: Influenza, pneumococcal, COVID-19 (per local guidance), plus hand hygiene and dental care.
Purpose: Lower risk of pneumonia and severe illness.
Mechanism: Immunization and hygiene reduce exposure and severity.Specialist palliative care (alongside active care)
Description: Symptom management, future planning, and family support from diagnosis onward.
Purpose: Improve comfort and quality of life throughout the illness.
Mechanism: Multidimensional care targets breathlessness, saliva, sleep, mood, and pain.
Drug treatments
(Key symptom-relief and disease-specific medicines. Doses are typical adult ranges; individual dosing and timing must be set by a clinician, considering kidney/liver function and interactions.)
Riluzole
Class: Glutamate release modulator (disease-modifying).
Typical dose/time: 50 mg by mouth twice daily, 1 hour before or 2 hours after meals.
Purpose: Modestly slows disease progression and may extend survival.
Mechanism: Lowers glutamatergic excitotoxicity on motor neurons.
Side effects: Nausea, fatigue, elevated liver enzymes; rare liver injury—needs periodic liver tests.Edaravone (IV or oral suspension)
Class: Free-radical scavenger (disease-modifying).
Typical dose/time: Approved cyclic dosing; IV infusions or oral per label.
Purpose: Slows functional decline in some patients, especially earlier disease.
Mechanism: Reduces oxidative stress in motor neurons.
Side effects: Headache, bruising, gait issues; IV form can cause infusion reactions.Tofersen (for confirmed SOD1-ALS)
Class: Antisense oligonucleotide (genetic therapy).
Typical dose/time: Intrathecal loading then maintenance, per specialist protocol.
Purpose: Slows biomarker rise (neurofilament) and may slow decline in SOD1 mutation carriers.
Mechanism: Lowers SOD1 protein production.
Side effects: Headache, back pain, spinal tap–related effects; requires genetic confirmation and specialty centers.Baclofen
Class: Antispasticity (GABA_B agonist).
Typical dose/time: Start 5 mg three times daily; titrate slowly (usual 30–80 mg/day).
Purpose: Reduce muscle stiffness and spasms.
Mechanism: Decreases spinal reflex activity.
Side effects: Sleepiness, weakness, dizziness; abrupt stop can cause withdrawal.Tizanidine
Class: Alpha-2 agonist antispasticity agent.
Typical dose/time: Start 2 mg at night; titrate to effect (usually up to 36 mg/day in divided doses).
Purpose: Ease spasticity when baclofen is not enough or not tolerated.
Mechanism: Reduces excitatory input to motor neurons.
Side effects: Drowsiness, dry mouth, low blood pressure; check liver tests.Intrathecal baclofen (ITB) via pump
Class: Antispasticity (spinal delivery).
Dose/time: Programmable pump provides continuous low-dose baclofen.
Purpose: Treat severe spasticity with fewer whole-body side effects.
Mechanism: Delivers drug directly into spinal fluid.
Side effects: Pump or catheter problems, infection, overdose/withdrawal if interrupted.Mexiletine
Class: Sodium-channel blocker (antiarrhythmic used off-label for cramps).
Typical dose/time: 150–300 mg/day in divided doses as tolerated.
Purpose: Reduce painful muscle cramps.
Mechanism: Stabilizes muscle membrane excitability.
Side effects: Heart rhythm effects, tremor, nausea; ECG monitoring advisable.Dextromethorphan/quinidine (for pseudobulbar affect)
Class: NMDA antagonist + CYP2D6 inhibitor combination.
Dose/time: As per product label (commonly 20/10 mg twice daily).
Purpose: Reduce sudden laughing/crying spells.
Mechanism: Modulates glutamate and sigma-1 pathways; quinidine boosts dextromethorphan levels.
Side effects: Dizziness, diarrhea, prolonged QT—review cardiac risks.Glycopyrrolate
Class: Anticholinergic for sialorrhea (drooling).
Dose/time: 1 mg 1–3 times daily, titrate carefully.
Purpose: Dry excess saliva to reduce choking and skin irritation.
Mechanism: Blocks muscarinic receptors in salivary glands.
Side effects: Dry mouth, constipation, blurry vision, confusion in sensitive patients.Atropine eye-drop sublingual use
Class: Anticholinergic.
Dose/time: 1% drops placed under tongue as directed by clinician.
Purpose: On-demand saliva control.
Mechanism: Local antimuscarinic effect on salivary flow.
Side effects: Dry mouth, tachycardia; avoid overuse.Scopolamine (hyoscine) transdermal patch
Class: Anticholinergic.
Dose/time: 1 patch every 72 hours behind ear.
Purpose: Longer-acting saliva control and motion-related nausea relief.
Mechanism: Central and peripheral antimuscarinic actions.
Side effects: Drowsiness, confusion, dry mouth, blurry vision.Botulinum toxin injections to salivary glands
Class: Local neuromuscular blocker (procedure-based drug).
Dose/time: Injected every 3–4 months by specialist.
Purpose: Reduce drooling without whole-body anticholinergic effects.
Mechanism: Blocks acetylcholine release at gland nerves.
Side effects: Thick saliva, swallowing difficulty if spread occurs.Short-acting opioids (e.g., low-dose morphine) for air hunger
Class: Opioid analgesic.
Dose/time: Very low dose as directed; careful monitoring.
Purpose: Ease breathlessness and anxiety tied to dyspnea.
Mechanism: Alters central perception of breathlessness and reduces ventilatory drive discomfort.
Side effects: Constipation, drowsiness; use with clinician oversight.SSRIs or SNRIs (e.g., sertraline, citalopram, duloxetine)
Class: Antidepressants.
Dose/time: Standard depression/anxiety dosing, titrated slowly.
Purpose: Treat depression, anxiety, and sometimes pseudobulbar affect if DM/Q unavailable.
Mechanism: Increases serotonin ± norepinephrine levels.
Side effects: GI upset, sleep changes, sexual side effects; watch interactions.Tricyclic antidepressants (e.g., amitriptyline)
Class: TCA antidepressant with anticholinergic effect.
Dose/time: Low dose at night (e.g., 10–25 mg), titrate.
Purpose: Help drooling, mood, sleep, and neuropathic pain.
Mechanism: Blocks reuptake of serotonin/norepinephrine; antimuscarinic action dries saliva.
Side effects: Dry mouth, constipation, drowsiness, QT effects in overdose.Sleep aids (e.g., melatonin; short-term zolpidem if needed)
Class: Hormonal supplement or sedative-hypnotic.
Dose/time: Melatonin 1–5 mg nightly; zolpidem lowest effective, short duration.
Purpose: Improve sleep quality disrupted by cramps or NIV adaptation.
Mechanism: Melatonin supports circadian rhythm; zolpidem enhances GABA_A.
Side effects: Morning grogginess; falls risk with sedatives.Laxatives (e.g., polyethylene glycol, senna)
Class: Osmotic or stimulant laxatives.
Dose/time: Daily PEG as powder; senna as directed.
Purpose: Prevent constipation from immobility, low fluids, and medications.
Mechanism: Draws water into stool or stimulates bowel movement.
Side effects: Bloating, cramps; avoid overuse.Mucolytics and expectorants (e.g., guaifenesin)
Class: Expectorant.
Dose/time: Per label.
Purpose: Thin mucus for easier clearance with cough assist.
Mechanism: Increases respiratory tract fluid.
Side effects: Nausea, dizziness.NSAIDs or acetaminophen
Class: Analgesics/anti-inflammatory (NSAIDs); analgesic/antipyretic (acetaminophen).
Dose/time: As needed, per label; consider stomach/kidney risks with NSAIDs.
Purpose: Treat musculoskeletal pain from posture or strain.
Mechanism: Reduces inflammatory mediators or central pain signaling.
Side effects: GI upset, kidney risk (NSAIDs); liver risk (acetaminophen overdose).Antireflux therapy (e.g., proton pump inhibitor)
Class: Acid-suppressing agent.
Dose/time: Daily before breakfast.
Purpose: Reduce reflux and aspiration risk, especially after gastrostomy.
Mechanism: Blocks acid pumps in stomach lining.
Side effects: Headache, diarrhea; long-term use reviewed periodically.
Dietary molecular supplements
(Evidence varies; none of these is a proven cure. Discuss with your clinician to avoid interactions and to check safety.)
High-calorie oral supplements
Dose: As needed to maintain or gain weight.
Function/mechanism: Provides energy and protein to slow weight loss and support breathing muscles.Omega-3 fatty acids (fish oil)
Dose: Commonly 1–2 g/day EPA+DHA total.
Function/mechanism: Anti-inflammatory membrane support; may help cardiovascular and general health.Vitamin D
Dose: Per blood levels; often 800–2000 IU/day, adjusted.
Function/mechanism: Bone and immune support, fracture risk reduction in immobility.Creatine
Dose: 3–5 g/day.
Function/mechanism: Cellular energy buffer in muscle; evidence mixed for function in ALS.Coenzyme Q10 (ubiquinone)
Dose: 100–300 mg/day.
Function/mechanism: Antioxidant in mitochondria; large ALS trials have not proven benefit, but may support general oxidative balance.Vitamin B12 (methylcobalamin, high-dose under supervision)
Dose: Protocols vary; high-dose injections studied; only with clinician oversight.
Function/mechanism: Nerve health and myelin support; ALS-specific benefit uncertain.Tauroursodeoxycholic acid (TUDCA)
Dose: Doses in studies vary (often 500–1000 mg twice daily); discuss safety.
Function/mechanism: Mitochondrial and ER-stress modulation; mixed trial results.L-carnitine/acetyl-L-carnitine
Dose: 1–2 g/day (divided).
Function/mechanism: Fatty-acid transport into mitochondria; may help energy metabolism; ALS efficacy unproven.Curcumin preparations
Dose: Per product; often 500–1000 mg/day of standardized extract.
Function/mechanism: Antioxidant/anti-inflammatory actions; bioavailability varies; disease-modifying effect unproven.Sialorrhea-friendly thickeners (food additives)
Dose: Used to thicken liquids as per speech therapist advice.
Function/mechanism: Slows liquid flow to improve swallow safety and reduce aspiration.
Immunity-booster / regenerative / stem-cell–oriented drugs
(Long description kept concise; these are not standard cures. Many remain investigational and should only be accessed in regulated clinical trials.)
Autologous mesenchymal stem cell (MSC) therapy (experimental)
Dose/route: Intrathecal or intravenous in trials.
Function/mechanism: Proposed neurotrophic and anti-inflammatory effects; efficacy in ALS unproven; risks include procedure complications.Neural progenitor cell grafts (experimental)
Dose/route: Surgical spinal injections in trials.
Function/mechanism: Aim to provide trophic support to motor neurons; long-term benefit uncertain; surgical risks exist.Gene-targeted antisense therapies beyond SOD1 (experimental)
Dose/route: Intrathecal dosing in mutation-specific trials (e.g., C9orf72).
Function/mechanism: Reduce toxic RNA or proteins; only for genetically confirmed subtypes.Immune-modulating small molecules (e.g., ibudilast; research use)
Dose: Per trial protocols only.
Function/mechanism: Target neuroinflammation and glial activation; clinical benefit not yet established.Cytoskeletal/neuromuscular activators (e.g., reldesemtiv; research use)
Dose: Per studies.
Function/mechanism: Increase muscle contractility efficiency to offset weakness; disease modification unproven.Neurotrophic factor strategies (experimental delivery systems)
Dose/route: Various trial methods (viral vectors, pumps).
Function/mechanism: Attempt to supply growth factors that support motor neuron survival; safety and efficacy still under study.
Procedures and surgeries
(Why they are done and what the procedure involves.)
Percutaneous endoscopic gastrostomy (PEG)
Procedure: A flexible tube is placed through the abdominal wall into the stomach using endoscopy.
Why: Ensures safe, reliable nutrition, hydration, and medication delivery when swallowing is unsafe.Radiologically inserted gastrostomy (RIG/PRG)
Procedure: Feeding tube placed using imaging instead of endoscopy—useful when breathing is fragile.
Why: Offers an alternative when PEG is risky due to poor lung function.Tracheostomy with invasive ventilation (TIV)
Procedure: Surgical opening in the neck into the windpipe connected to a ventilator.
Why: Provides long-term breathing support when non-invasive ventilation is no longer enough; requires major caregiving resources.Intrathecal baclofen pump implantation
Procedure: A pump is placed under the skin with a catheter into spinal fluid.
Why: Treats severe spasticity with fewer systemic side effects than high-dose oral baclofen.Salivary gland duct procedures (ligation/neurectomy) or targeted radiotherapy
Procedure: Surgical or radiologic techniques to reduce saliva production when medications and botulinum toxin fail.
Why: Control severe drooling to improve comfort and lower aspiration risk.
(Note: “Diaphragm pacing” is generally not recommended in ALS due to lack of benefit and possible harm in trials.)
Preventions
Prevent malnutrition by early dietician input and timely feeding tube planning.
Prevent aspiration with swallow strategies, texture changes, and upright eating.
Prevent respiratory infections with NIV optimization, cough assist, vaccines, and oral hygiene.
Prevent falls by home safety checks, proper footwear, and mobility aids.
Prevent pressure injuries with cushions, mattresses, and regular repositioning.
Prevent contractures by daily stretching and splints.
Prevent constipation with fluids, fiber as tolerated, and laxatives when needed.
Prevent depression/anxiety through early counseling and, if needed, medication.
Prevent caregiver burnout with respite care, training, and support groups.
Prevent medication complications with careful review of drug lists and liver function tests when required.
When to see doctors (red flags)
New or worsening shortness of breath, morning headaches, or disturbed sleep—may need NIV.
Frequent choking, weight loss, dehydration, or long mealtimes—needs swallow and nutrition review.
Recurrent chest infections or difficulty clearing mucus—needs airway clearance plan.
Falls, severe cramps, or painful stiffness—PT/OT and medication adjustment can help.
Sudden mood changes, severe sadness, or loss of interest—mental health care is important.
Any rapid decline or new neurological symptoms—urgent reassessment.
Before travel, surgery, or new medication—ALS team should plan safety steps.
What to eat and what to avoid
Eat soft, moist, high-calorie meals (e.g., yogurt, eggs, mashed foods, smoothies).
Eat small, frequent meals to reduce fatigue and keep calories up.
Eat adequate protein (dairy, eggs, fish, legumes) to support muscles.
Drink enough fluids; use thickeners if liquids cause coughing.
Add healthy fats (nut butters, olive oil, avocado) for extra energy.
Limit dry, crumbly foods (crackers, dry bread) that are easy to choke on.
Avoid alcohol excess and sedatives near meals—they worsen swallowing and balance.
Avoid very spicy or acidic foods if they trigger reflux or coughing.
Review all supplements with your clinician to avoid drug interactions.
Plan with a dietitian early; consider a feeding tube before weight drops.
Frequently Asked Questions
What is ALS without FTD?
ALS damages motor neurons causing muscle weakness and breathing problems, but without major changes in thinking or personality seen in frontotemporal dementia.What causes ALS?
Most cases are sporadic (no clear cause). About 5–10% are genetic (inherited mutations like SOD1 or C9orf72).Is it contagious?
No. ALS does not spread from person to person.How is ALS diagnosed?
By a neurologist using history, exam, nerve and muscle tests (EMG/NCS), and ruling out other conditions with blood tests and imaging.How fast does ALS progress?
It varies widely. Some people progress quickly; others more slowly. Early nutrition and breathing support can improve outcomes.Can medicines slow the disease?
Yes—riluzole and edaravone can slow decline for some. Tofersen may help people with SOD1 mutations. None is a cure.Will I lose my ability to speak or swallow?
Many people develop speech and swallow problems. Early speech therapy, diet changes, AAC, and timely feeding tube help a lot.What about breathing failure?
NIV (mask ventilation) helps symptoms and may extend life. Some choose tracheostomy ventilation; others focus on comfort care.Does exercise help?
Gentle, sub-maximal exercise and stretching can maintain flexibility and mood. Avoid exhausting workouts that worsen fatigue.Do vitamins or supplements cure ALS?
No proven cure. Some supplements support general health, but benefits for ALS are uncertain. Discuss safety with your doctor.Are stem cells a cure?
Not at this time. Stem-cell approaches remain experimental and should only be used within regulated clinical trials.Can I keep working or driving?
Many continue for a time with adaptations. Regular safety checks, workplace adjustments, and honest discussion with your team are important.Will I have pain?
ALS nerves for pain usually remain intact; however, cramps, stiffness, and immobility can cause pain. Multiple treatments can help.How can family and caregivers cope?
Education, respite services, counseling, and support groups reduce stress and improve care quality.Where can I find trustworthy help?
Neuromuscular specialist clinics, national ALS associations, and peer groups provide reliable information and practical services.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 15, 2025.
